NCT06784726 2026-03-13
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
Phase 2 Recruiting
Clinical Trials
94 trialsNCT07463781 2026-03-13
NEURO_CAR-T
Fondazione Italiana Linfomi - ETS
Not yet recruiting
NCT07340853 2026-03-10
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT07458659 2026-03-09
CART-BCMA
Chulalongkorn University
Phase EARLY_PHASE1 Not yet recruiting
NCT07454226 2026-03-06
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Not yet recruiting
NCT06481228 2026-03-02
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT06481241 2026-03-02
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT03434769 2026-02-27
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04512716 2026-02-17
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT07052305 2026-02-12
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Washington University School of Medicine
Phase 1 Recruiting
NCT05800405 2026-02-04
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
City of Hope Medical Center
Phase EARLY_PHASE1 Recruiting
NCT07374029 2026-01-28
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Beth Israel Deaconess Medical Center
Phase 1 Not yet recruiting
NCT04180059 2026-01-26
CTL-DP 01
Nantes University Hospital
Phase 1 Recruiting
NCT04995003 2026-01-22
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Baylor College of Medicine
Phase 1 Recruiting
NCT04545762 2026-01-14
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
Phase 1 Recruiting
NCT06104592 2026-01-08
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT03277729 2026-01-05
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Fred Hutchinson Cancer Center
Phase 1/2 Active not recruiting
NCT05260957 2025-12-31
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
University of Miami
Phase 2 Recruiting
NCT04670068 2025-12-22
Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06218602 2025-12-16
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07280494 2025-12-12
S101MRD
Peking University People's Hospital
Phase 1 Recruiting
NCT06649227 2025-12-05
CARLA-M19
University Hospital, Lille
Phase 1 Recruiting
NCT07261163 2025-12-03
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07053670 2025-11-17
CT1190B
Tongji Hospital
Phase 1 Recruiting
NCT06854159 2025-09-29
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
University of California, Davis
Phase 2 Recruiting
NCT04007029 2025-09-05
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT07153289 2025-09-03
ResCPa
University Hospital Tuebingen
Phase 1/2 Not yet recruiting
NCT04008524 2025-08-06
A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
Institute of Hematology & Blood Diseases Hospital, China
Available
NCT07097207 2025-07-31
CAR-T
Shenzhen University General Hospital
Phase 1/2 Recruiting
NCT07094477 2025-07-30
Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma
Chinese PLA General Hospital
Phase 2 Active not recruiting
NCT02917083 2025-07-25
RELY-30
Baylor College of Medicine
Phase 1 Recruiting
NCT04577326 2025-07-25
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05225363 2025-07-01
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT03241940 2025-06-29
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
Phase 1 Active not recruiting
NCT07043218 2025-06-29
A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase 1 Not yet recruiting
NCT06815029 2025-06-26
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
City of Hope Medical Center
Phase 1 Recruiting
NCT03186118 2025-06-17
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT07020260 2025-06-13
PACMAN
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Not yet recruiting
NCT02100891 2025-03-19
STIR
Medical College of Wisconsin
Phase 2 Terminated
NCT06822868 2025-02-12
CT1190B
Beijing GoBroad Hospital
Phase 1 Recruiting
NCT06796517 2025-01-28
Immunotherapy in Lymphoma
Seoul St. Mary's Hospital
Recruiting
NCT06752785 2024-12-31
CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
Guangzhou Women and Children's Medical Center
Phase 1 Recruiting
NCT06698484 2024-11-21
CAR-T for NHL
National University of Malaysia
Phase 2 Recruiting
NCT05587543 2024-11-12
Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
Fudan University
Phase EARLY_PHASE1 Recruiting
NCT03919240 2024-10-24
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
The First Affiliated Hospital of Soochow University
Phase 1/2 Active not recruiting
NCT06647329 2024-10-17
CAR-T Therapy
Zhengzhou University
Phase 1 Not yet recruiting
NCT05202782 2024-10-16
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
Northwestern University
Phase 2 Active not recruiting
NCT06642025 2024-10-15
EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia
The Second Hospital of Anhui Medical University
Phase EARLY_PHASE1 Recruiting
NCT05779917 2024-06-25
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
Second Affiliated Hospital of Guangzhou Medical University
Phase 1 Recruiting
NCT06429150 2024-06-10
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting